Your browser doesn't support javascript.
loading
Impact of the CYP2C8 *3 polymorphism on the drug-drug interaction between gemfibrozil and pioglitazone.
Aquilante, Christina L; Kosmiski, Lisa A; Bourne, David W A; Bushman, Lane R; Daily, Elizabeth B; Hammond, Kyle P; Hopley, Charles W; Kadam, Rajendra S; Kanack, Alexander T; Kompella, Uday B; Le, Merry; Predhomme, Julie A; Rower, Joseph E; Sidhom, Maha S.
Affiliation
  • Aquilante CL; Department of Pharmaceutical Sciences, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO 80045, USA. christina.aquilante@ucdenver.edu
Br J Clin Pharmacol ; 75(1): 217-26, 2013 Jan.
Article in En | MEDLINE | ID: mdl-22625877
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Polymorphism, Genetic / Aryl Hydrocarbon Hydroxylases / Gemfibrozil / Thiazolidinediones / Hypolipidemic Agents Type of study: Clinical_trials / Prognostic_studies Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: Br J Clin Pharmacol Year: 2013 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Polymorphism, Genetic / Aryl Hydrocarbon Hydroxylases / Gemfibrozil / Thiazolidinediones / Hypolipidemic Agents Type of study: Clinical_trials / Prognostic_studies Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: Br J Clin Pharmacol Year: 2013 Document type: Article Affiliation country: Country of publication: